STSS - NASDAQ
Sharps Technology, Inc.
$1.84
+1.1%Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
At a Glance
Live SnapshotSharps Technology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Sharps Technology, Inc. Cash Flow Statement
STSS • NASDAQ
| Sharps Technology, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-270.3M | -9.3M | -9.8M | -4.6M | -4.7M | -2.3M | -2.1M | |
132.5K | 773.9K | 882.2K | 654.6K | 28.7K | 11K | 10.6K | |
0.0 | -30K | -30K | 0.0 | 0.0 | 0.0 | 25.8K | |
107.5M | 520.8K | 963K | 1M | 1.2M | 485.2K | 399.0 | |
143.2M | 1.5M | 640K | -3.3M | 179.5K | 10.2K | 372.6K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.1K) | (0.0) | |
2.8M | -426.2K | -1.1M | -209.2K | 112.6K | -49.2K | 72.4K | |
-16.7M | -6.9M | -8.5M | -6.4M | -3.1M | -1.9M | -1.6M | |
INVESTING ACTIVITIES | |||||||
(0.0) | -138.8K | -698.3K | -752.3K | -2.3M | -312.2K | -11.2K | |
-187.5M | (0.0) | (0.0) | -209.7K | (0.0) | (0.0) | (0.0) | |
-1.6M | -1M | 0.0 | -2.2M | -75K | -75K | 0.0 | |
-189.2M | -1.2M | -698.3K | -3.1M | -2.3M | -387.2K | -11.2K | |
FINANCING ACTIVITIES | |||||||
212.1M | 3.4M | 8M | 14.2M | 3.4M | 3.4M | 1.7M | |
3.4M | 2.5M | 0.0 | -2M | 1.8M | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -162.5K | |
0.0 | 0.0 | 0.0 | 32.5K | 0.0 | 0.0 | 180K | |
215.5M | 5.9M | 8M | 12.2M | 5.2M | 3.4M | 1.8M | |
CASH FLOW SUMMARY | |||||||
-250K | 36.4K | 18K | 7.3K | 0.0 | 0.0 | -249.5K | |
9.4M | -2.1M | -1.2M | 2.7M | -311K | 1.2M | 636.0 | |
1M | 3M | 4.2M | 1.5M | 1.8M | 635.5K | 634.9K | |
10.4M | 864K | 3M | 4.2M | 1.5M | 1.8M | 635.5K | |
-16.7M | -7.1M | -9.2M | -7.2M | -5.4M | -2.2M | -1.6M |
SEC Filings
STSS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | December 23, 2025 | December 23, 2025 | ||
8-K 8-K 2025 N/A | December 23, 2025 | December 19, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | December 23, 2025 | December 23, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your STSS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.